Publications by authors named "M J Agterof"
Background: Patients with stage II-III HER2-positive breast cancer have good outcomes with the combination of neoadjuvant chemotherapy and HER2-targeted agents. Although increasing the number of chemotherapy cycles improves pathological complete response rates, early complete responses are common. We investigated whether the duration of chemotherapy could be tailored on the basis of radiological response.
View Article and Find Full Text PDFAccurate prediction of response to neoadjuvant chemotherapy (NAC) can help tailor treatment to individual patients' needs. Little is known about the combination of liquid biopsies and computer extracted features from multiparametric magnetic resonance imaging (MRI) for the prediction of NAC response in breast cancer. Here, we report on a prospective study with the aim to explore the predictive potential of this combination in adjunct to standard clinical and pathological information before, during and after NAC.
View Article and Find Full Text PDFArticle Synopsis
- * A study of 9 patients post-RYGB showed that most did not achieve therapeutic levels of the antihormonal drug tamoxifen at the standard dosage, leading to a recommendation for a higher starting dose in some cases.
- * Patients with altered CYP2D6 metabolism may need to switch to different treatments, and while no dose adjustments were necessary for other drugs like anastrozole and letrozole, ongoing monitoring for effectiveness is still advised.
Real-world palbociclib effectiveness in patients with metastatic breast cancer: Focus on neutropenia-related treatment modification strategies and clinical outcomes.
Cancer Treat Res Commun
May 2023
Article Synopsis
- The study investigates real-world treatment strategies for neutropenia in patients taking palbociclib, focusing on their impact on progression-free survival (PFS) against outcomes in clinical trials.
- Data from 229 patients with HR-positive, HER2-negative metastatic breast cancer were analyzed, revealing different treatment modifications compared to the PALOMA-3 clinical trial, but no significant effect on PFS.
- Patients deemed ineligible for the PALOMA-3 trial had shorter PFS, emphasizing that real-world outcomes may differ from those observed in clinical trials.
Purpose: CompLEEment-1 (NCT02941926) is a single-arm, open-label, multicentre phase IIIb study investigating the safety and efficacy of ribociclib plus letrozole (RIB + LET) in a large, diverse cohort who have not received prior endocrine therapy (ET) for advanced disease. We present an exploratory analysis of male patients.
Methods: Eligible patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC), who had no prior ET and ≤ 1 line of prior chemotherapy for advanced disease, received RIB + LET.